Semaglutide
Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is a drug used to treat type 2 diabetes and reduce obesity. It was developed by Novo Nordisk in 2012.[1] It was approved for use in America in 2017.[2] It was approved in Europe in 2022 [3] and in the National Health Service in 2023.
People who had the weekly injection saw their weight drop by 12% on average after 68 weeks.[4] It is also prescribed for heart conditions.[5]
Semaglutide Media
An Ozempic pen sold in China
References
- ↑ Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine (27 Oct 2021).
- ↑ Ozempic (semaglutide) FDA Approval History (in en). Drugs.com. Retrieved 2023-03-08.
- ↑ EMA. Wegovy (in en). European Medicines Agency (2021-11-11). Retrieved 2023-03-08.
- ↑ PA. Weight loss injection popular with celebrities is approved for NHS use (in en). Manchester Evening News (2023-03-08). Retrieved 2023-03-08.
- ↑ Kuchler, Hannah (2023-09-01). "Novo Nordisk briefly eclipses LVMH as Europe’s most valuable company". Financial Times. https://www.ft.com/content/97e89e94-38cb-4a22-9a17-c110e39958bc?. Retrieved 2023-09-02.